Gene-edited Autologous Neoantigen-targeted NeoTCR-P1 T-cells

**Semantic type:** Cell|Pharmacologic Substance

**Definition:** A preparation of autologous CD4- and CD8-positive T-lymphocytes that have been engineered with site-specific nucleases to suppress the expression of most endogenous forms of the T-cell receptor (TCR) and promote expression of a single, native TCR targeting a neoepitope that is presented on the surface of a patient's tumor cells, with potential immunostimulating and antineoplastic activities. Upon reintroduction into the patient, the gene-edited autologous neoantigen-targeted NeoTCR-P1 T-cells recognize and bind to tumor cells expressing the targeted neoantigen, resulting in a cytotoxic T-lymphocyte (CTL)-mediated immune response against the patient's tumor cells.

**Synonyms:** - NeoTCR-P1 - NeoTCR-P1 T-cells